Obama's Trade Policy Ensures Big Pharma Profit at Expense of World's Poor: Report
In a bid that will bolster profits for western pharmaceutical corporations at the expense of the world's most vulnerable, the Obama administration is pushing international drug pricing policies that would ensure elevated prices for essential medicines across the developing world, according to a report by the Huffington Post.
The report explores how the Obama administration's U.S. Patent and Trademark Office (USPTO) has increasingly sought to intensify western pharmaceutical patent and data exclusivity rules through international trade negotiations such as the Trans-Pacific Partnership (TPP), which allow for steep increases in drug prices around the world. United Nations groups, the World Health Organization, and many human rights lawyers and patient advocates argue these corporation-friendly rules greatly oppress sick patients in developing countries.
"We're taking the worst parts of U.S. law, the parts that make these medications unavailable to patients, and putting them into a trade policy as a guiding principle for developing countries. That's ridiculous," Reshma Ramachandran, a fellow with the American Medical Student Association, told the Huffington Post.
USPTO Deputy Director Teresa Stanek Rea has recently embarked on a campaign to put an end to what is known as an international 'compulsory licensing' law -- a rule that allows local pharmaceutical companies in countries such as India to produce 'generic' drugs in competition with western corporations. The generic versions are far more affordable than imported 'brand name' drugs from the west.
Revoking protections for 'generic drugs' would allow the continued domination of developing markets by western pharmaceutical companies. "It's disappointing and outrageous. Compulsory licensing is a sovereign right to protect public health and other public interests," stated Peter Maybarduk, director of Public Citizen's Access to Medicines Program.
"That the Obama administration cannot see the gross inequity of charging $5000 per person per month for a cancer medicine in a developing country says a lot about this government," says Shiba Phurailpatam of the Asia Pacific Network of people living with HIV/AIDS. "Affordable care, it seems, is only for U.S. citizens, not for the developing world."
The Trans-Pacific Partnership negotiations, which are slated to give unprecedented political authority to multinational corporations and are being used to push through such policies, have gone on for two years between the Obama administration and several Pacific nations under conditions of 'extreme secrecy'.
# # #
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
In a bid that will bolster profits for western pharmaceutical corporations at the expense of the world's most vulnerable, the Obama administration is pushing international drug pricing policies that would ensure elevated prices for essential medicines across the developing world, according to a report by the Huffington Post.
The report explores how the Obama administration's U.S. Patent and Trademark Office (USPTO) has increasingly sought to intensify western pharmaceutical patent and data exclusivity rules through international trade negotiations such as the Trans-Pacific Partnership (TPP), which allow for steep increases in drug prices around the world. United Nations groups, the World Health Organization, and many human rights lawyers and patient advocates argue these corporation-friendly rules greatly oppress sick patients in developing countries.
"We're taking the worst parts of U.S. law, the parts that make these medications unavailable to patients, and putting them into a trade policy as a guiding principle for developing countries. That's ridiculous," Reshma Ramachandran, a fellow with the American Medical Student Association, told the Huffington Post.
USPTO Deputy Director Teresa Stanek Rea has recently embarked on a campaign to put an end to what is known as an international 'compulsory licensing' law -- a rule that allows local pharmaceutical companies in countries such as India to produce 'generic' drugs in competition with western corporations. The generic versions are far more affordable than imported 'brand name' drugs from the west.
Revoking protections for 'generic drugs' would allow the continued domination of developing markets by western pharmaceutical companies. "It's disappointing and outrageous. Compulsory licensing is a sovereign right to protect public health and other public interests," stated Peter Maybarduk, director of Public Citizen's Access to Medicines Program.
"That the Obama administration cannot see the gross inequity of charging $5000 per person per month for a cancer medicine in a developing country says a lot about this government," says Shiba Phurailpatam of the Asia Pacific Network of people living with HIV/AIDS. "Affordable care, it seems, is only for U.S. citizens, not for the developing world."
The Trans-Pacific Partnership negotiations, which are slated to give unprecedented political authority to multinational corporations and are being used to push through such policies, have gone on for two years between the Obama administration and several Pacific nations under conditions of 'extreme secrecy'.
# # #
In a bid that will bolster profits for western pharmaceutical corporations at the expense of the world's most vulnerable, the Obama administration is pushing international drug pricing policies that would ensure elevated prices for essential medicines across the developing world, according to a report by the Huffington Post.
The report explores how the Obama administration's U.S. Patent and Trademark Office (USPTO) has increasingly sought to intensify western pharmaceutical patent and data exclusivity rules through international trade negotiations such as the Trans-Pacific Partnership (TPP), which allow for steep increases in drug prices around the world. United Nations groups, the World Health Organization, and many human rights lawyers and patient advocates argue these corporation-friendly rules greatly oppress sick patients in developing countries.
"We're taking the worst parts of U.S. law, the parts that make these medications unavailable to patients, and putting them into a trade policy as a guiding principle for developing countries. That's ridiculous," Reshma Ramachandran, a fellow with the American Medical Student Association, told the Huffington Post.
USPTO Deputy Director Teresa Stanek Rea has recently embarked on a campaign to put an end to what is known as an international 'compulsory licensing' law -- a rule that allows local pharmaceutical companies in countries such as India to produce 'generic' drugs in competition with western corporations. The generic versions are far more affordable than imported 'brand name' drugs from the west.
Revoking protections for 'generic drugs' would allow the continued domination of developing markets by western pharmaceutical companies. "It's disappointing and outrageous. Compulsory licensing is a sovereign right to protect public health and other public interests," stated Peter Maybarduk, director of Public Citizen's Access to Medicines Program.
"That the Obama administration cannot see the gross inequity of charging $5000 per person per month for a cancer medicine in a developing country says a lot about this government," says Shiba Phurailpatam of the Asia Pacific Network of people living with HIV/AIDS. "Affordable care, it seems, is only for U.S. citizens, not for the developing world."
The Trans-Pacific Partnership negotiations, which are slated to give unprecedented political authority to multinational corporations and are being used to push through such policies, have gone on for two years between the Obama administration and several Pacific nations under conditions of 'extreme secrecy'.
# # #